Disease · MONDO_0005342

IgA glomerulonephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. IgA glomerulonephritis. Diseases, record MONDO_0005342. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005342

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: IgA glomerulonephritis; Open Targets
Open Targets ID: MONDO_0005342; Open Targets
Other names: Berger Disease, Berger's disease, Glomerulonephritis, IGA, IgA Nephropathy, IgAN, Immunoglobulin A Nephropathy, Nephropathy, IGA; Open Targets
Disease Ontology: DOID:2986; Disease Ontology
MeSH: D005922; MeSH
NCI Thesaurus: C34643; NCI Thesaurus
Orphanet: ORPHA:34145; Orphanet
Highest stage of its drugs: Approval, for 3 of its 73 drugs, from EMA Human Drugs, FDA and TTD; Open Targets

Drugs73

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUDESONIDE	CHEMBL1370	Small molecule	Approval	EMA Human Drugs	10	8	6	Drugs and targets
SPARSENTAN	CHEMBL539423	Small molecule	Approval	EMA Human Drugs, FDA and TTD	8	5	5	Drugs and targets
IPTACOPAN HYDROCHLORIDE	CHEMBL5095401	Small molecule	Approval	FDA	1	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	11	11	8	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	7	7	4	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	7	7	4	Drugs and targets
TELITACICEPT	CHEMBL5095293	Protein	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
IPTACOPAN	CHEMBL4594448	Small molecule	Phase 3	ClinicalTrials.gov and TTD	6	5	5	Drugs and targets
ATACICEPT	CHEMBL1742986	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 73

See all 73 drugs

Targets67

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	6	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
ACE	Angiotensin-converting enzyme	2	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
C5	Complement C5	2	Complement C5 inhibitor; Complement C5 mRNA RNAi inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	2	Lymphocyte differentiation antigen CD38 binding agent; Lymphocyte differentiation antigen CD38 inhibitor	Phase 3	https://conductscience.org/library/genes/952	Drugs and targets
CFB	Complement factor B	2	Complement factor B inhibitor	Approval	https://conductscience.org/library/genes/629	Drugs and targets
EDNRA	Endothelin-1 receptor	2	Endothelin receptor ET-A antagonist	Approval	https://conductscience.org/library/genes/1909	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
SYK	Tyrosine-protein kinase SYK	2	Tyrosine-protein kinase SYK inhibitor	Phase 2	https://conductscience.org/library/genes/6850	Drugs and targets
TLR7	Toll-like receptor 7	2	Toll-like receptor 7 antagonist	Phase 2	https://conductscience.org/library/genes/51284	Drugs and targets

1 to 10 of 67

See all 67 targets

Trials105

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03762850	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Phase 3	406	2024-07-03	Immunoglobulin A Nephropathy	DAPAGLIFLOZIN, SPARSENTAN	Its record names the disease	ClinicalTrials.gov
NCT03643965	Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy	Phase 3	365	2024-12-03	Primary IgA Nephropathy	BUDESONIDE	Its record names the disease	ClinicalTrials.gov
NCT03608033	Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy	Phase 3	360	2025-12-09	IgA Nephropathy	NARSOPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT00318474	Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy	Phase 3	184	2014-10-01	IgA Nephropathy	MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT04287985	Safety and Efficacy Study of VIS649 for IgA Nephropathy	Phase 2	155	2024-11-21	Immunoglobulin A Nephropathy, Glomerular Disease, IgAN	SIBEPRENLIMAB	Its record names the disease	ClinicalTrials.gov
NCT04564339	Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	Phase 2	123	2026-01-22	Lupus Nephritis, Immunoglobulin A Nephropathy	RAVULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03373461	Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation	Phase 2	112	2022-10-07	IgA Nephropathy	IPTACOPAN	Its record names the disease	ClinicalTrials.gov
NCT03366337	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX	Phase 2	103	2022-01-18	IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney	BARDOXOLONE METHYL	Its record names the disease	ClinicalTrials.gov
NCT05097989	Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	Phase 2	100	2025-10-15	Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN	VEMIRCOPAN	Its record names the disease	ClinicalTrials.gov
NCT02112838	Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2	76	2019-06-27	IGA Nephropathy	FOSTAMATINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 105

See all 105 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sparsentan vs Irbesartan: deaths from any cause	0 of 202	1 of 202	404	NCT03762850	Trial comparisons
Sparsentan vs Irbesartan: serious adverse events	75 of 202	71 of 202	404	NCT03762850	Trial comparisons
Nefecon vs Placebo Oral Capsule: Part B: Proportion of Patients Without Microhematuria	94 of 182	59 of 182	364	NCT03643965	Trial comparisons
Nefecon vs Placebo Oral Capsule: Part B: Time to 30% Reduction in eGFR	21 of 182	39 of 182	364	NCT03643965	Trial comparisons
Nefecon vs Placebo Oral Capsule: Part B: Time to Receiving Rescue Medication.	15 of 182	20 of 182	364	NCT03643965	Trial comparisons
Nefecon vs Placebo Oral Capsule: deaths from any cause	1 of 182	0 of 182	364	NCT03643965	Trial comparisons
Nefecon vs Placebo Oral Capsule: serious adverse events	18 of 182	9 of 182	364	NCT03643965	Trial comparisons
OMS721 vs Placebo: Safety and Tolerability of Narsoplimab for the Treatment of IgAN as Assessed by AEs, Vital Signs, Clinical Laboratory Tests, and ECGs	181 of 181	179 of 179	360	NCT03608033	Trial comparisons
Mycophenolate Mofetil (MMF) vs Placebo: serious adverse events	1 of 25	1 of 27	52	NCT00318474	Trial comparisons
Allopurinol Group vs Control Group: serious adverse events	0 of 21	0 of 19	40	NCT00793585	Trial comparisons

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37916620	RESULT	1	PubMed
28763548	RESULT	1	PubMed
28341274	RESULT	1	PubMed
26630142	RESULT	1	PubMed
23782179	RESULT	1	PubMed
17699247	RESULT	1	PubMed
14694168	RESULT	1	PubMed
11877568	RESULT	1	PubMed
10676716	RESULT	1	PubMed
10093981	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005342

GET https://conductscience.org/api/diseases/v1/MONDO_0005342/drugs?page=2

API reference For AI assistants